These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 18971882)

  • 1. Analysis of factors interfering with the acceptance of interferon therapy by HCV-infected patients.
    Nagao Y; Kawakami Y; Yoshiyama T; Sata M
    Med Sci Monit; 2008 Nov; 14(11):PI45-52. PubMed ID: 18971882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Necessities of interferon therapy in elderly patients with chronic hepatitis C.
    Ikeda K; Arase Y; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Suzuki F; Suzuki Y; Kumada H
    Am J Med; 2009 May; 122(5):479-86. PubMed ID: 19375558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High incidence of multiple primary carcinomas in HCV-infected patients with oral squamous cell carcinoma.
    Nagao Y; Sata M
    Med Sci Monit; 2009 Sep; 15(9):CR453-9. PubMed ID: 19721396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does interferon use prior to liver transplant influence hepatitis C outcomes following transplantation?
    Smallwood GA; Devine R; Fasola C; Stieber AC; Heffron TG
    Transplantation; 2008 Dec; 86(12):1795-8. PubMed ID: 19104424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psychopathological changes and quality of life in hepatitis C virus-infected, opioid-dependent patients during maintenance therapy.
    Schäfer A; Wittchen HU; Backmund M; Soyka M; Gölz J; Siegert J; Schäfer M; Tretter F; Kraus MR
    Addiction; 2009 Apr; 104(4):630-40. PubMed ID: 19335661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of hepatocellular carcinoma developed after achieving sustained virological response to interferon therapy for hepatitis C.
    Sanefuji K; Kayashima H; Iguchi T; Sugimachi K; Yamashita Y; Yoshizumi T; Soejima Y; Nishizaki T; Taketomi A; Maehara Y
    J Surg Oncol; 2009 Jan; 99(1):32-7. PubMed ID: 18985618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis.
    Roche B; Sebagh M; Canfora ML; Antonini T; Roque-Afonso AM; Delvart V; Saliba F; Duclos-Vallee JC; Castaing D; Samuel D
    Liver Transpl; 2008 Dec; 14(12):1766-77. PubMed ID: 19025933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intra portal donor specific antigen transfusion might prevent re-infection of hepatitis C virus after living related liver transplantation in hepatitis C hepatic cirrhosis.
    Sato Y; Oya H; Yamamoto S; Kobayashi T; Watanabe T; Kokai H; Yamagiwa S; Hatakeyama K
    Hepatogastroenterology; 2009; 56(89):205-7. PubMed ID: 19453058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors associated with adherence to combination therapy of interferon and ribavirin for patients with chronic hepatitis C: importance of patient's motivation and physician's treatment experience.
    Tanioka D; Iwasaki Y; Araki Y; Osawa T; Ikeda H; Ando M; Kobashi H; Sakaguchi K; Shiratori Y; Yamamoto K
    Liver Int; 2009 May; 29(5):721-9. PubMed ID: 19141025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of interferon therapy after curative treatment of hepatocellular carcinoma.
    Kudo M
    Oncology; 2008; 75 Suppl 1():30-41. PubMed ID: 19092270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis.
    Yang YF; Zhao W; Zhong YD; Xia HM; Shen L; Zhang N
    J Viral Hepat; 2009 Apr; 16(4):265-71. PubMed ID: 19220736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus.
    Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2009 Jun; 81(6):1032-9. PubMed ID: 19382270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of genetic polymorphisms with interferon-induced haematologic adverse effects in chronic hepatitis C patients.
    Wada M; Marusawa H; Yamada R; Nasu A; Osaki Y; Kudo M; Nabeshima M; Fukuda Y; Chiba T; Matsuda F
    J Viral Hepat; 2009 Jun; 16(6):388-96. PubMed ID: 19200137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute hepatitis C: prevention and treatment.
    Ozaras R; Tahan V
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):351-61. PubMed ID: 19344247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiviral treatment for hepatitis C virus infection: effectiveness at general population level in a highly endemic area.
    Mariano A; Caserta C; Pendino GM; Vacalebre C; Surace P; Fiorillo MT; Polito I; Surace M; Alicante S; Amante A; Foti G; Marra M; Gutamo G; Amato F; Messineo A; Mele A
    Dig Liver Dis; 2009 Jul; 41(7):509-15. PubMed ID: 19196557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy with transarterial chemoembolization and interferon-alpha compared with transarterial chemoembolization alone for hepatitis B virus related unresectable hepatocellular carcinoma.
    Li M; Lu C; Cheng J; Zhang J; Cao C; Xu J; Xu J; Pan H; Zhong B; Tucker S; Wang D
    J Gastroenterol Hepatol; 2009 Aug; 24(8):1437-44. PubMed ID: 19486255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in viral kinetics between genotypes 1 and 2 of hepatitis C virus after single administration of standard interferon-alpha.
    Toyoda H; Kumada T; Kiriyama S; Sone Y; Tanikawa M; Hisanaga Y; Kanamori A; Atsumi H; Takagi M; Nakano S; Arakawa T; Fujimori M
    J Med Virol; 2009 Aug; 81(8):1354-62. PubMed ID: 19551828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence, risk factors, and outcome of chronic rejection during antiviral therapy for posttransplant recurrent hepatitis C.
    Fernández I; Ulloa E; Colina F; Abradelo M; Jiménez C; Gimeno A; Meneu JC; Lumbreras C; Solís-Herruzo JA; Moreno E
    Liver Transpl; 2009 Aug; 15(8):948-55. PubMed ID: 19642125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics and outcome of patients with dual hepatitis B and C-associated hepatocellular carcinoma: are they different from patients with single virus infection?
    Huo TI; Huang YH; Hsia CY; Su CW; Lin HC; Hsu CY; Lee PC; Lui WY; Loong CC; Chiang JH; Chiou YY; Lee SD
    Liver Int; 2009 May; 29(5):767-73. PubMed ID: 19018974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors influencing renal function after liver transplantation. Results from the MOST, an international observational study.
    Burra P; Senzolo M; Masier A; Prestele H; Jones R; Samuel D; Villamil F
    Dig Liver Dis; 2009 May; 41(5):350-6. PubMed ID: 19046932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.